GEN Exclusives

More »
Readers Comments Back to Item »

Paring, Sharing, and Snaring: Big Pharma's Latest R&D

1 Readers' Comments

Posted by: Jinjing LI

03/31/2011

<font face="Times New Roman"><span lang="EN-US">Crystal Pharmatech Co.,Ltd researchers held an incredibly successful two-day training program on polymorphism and solid state characterization</span><span style="mso-fareast-font-family: ??; mso-fareast-language: ZH-CN;" lang="EN-US"> </span><span lang="EN-US">at Suzhou Industrial Park, China March 24<sup>th</sup> and 25<sup>th</sup>.<span style="mso-spacerun: yes;">  </span>The training program was attended by over 130 researchers representing more than 7</span><span style="mso-fareast-font-family: ??; mso-fareast-language: ZH-CN;" lang="EN-US">0</span><span lang="EN-US"> China based pharmaceutical companies.<span style="mso-spacerun: yes;">  </span>Attendees included senior scientists and managers from global Pharm R&D centers in China including GSK, Novartis, Roche as well as other leading China-based companies including Huahai, Hengrui, and Donyangguang.<span style="mso-spacerun: yes;">  </span></span></font>

  • Click here to Login or to Register for free.

    You will be taken back to your selected item after Login/Registration.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?